PerkinElmer with ticker code (PKI) now have 12 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 200 and 125 calculating the mean target price we have 171.25. Given that the stocks previous close was at 150.69 this would indicate that there is a potential upside of 13.6%. The 50 day MA is 143.85 and the 200 moving average now moves to 167.01. The market capitalisation for the company is $19,962m. Visit the company website at: https://www.perkinelmer.com
The potential market cap would be $22,686m based on the market concensus.
PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer was founded in 1937 and is headquartered in Waltham, Massachusetts.
